FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy.
Saved in:
| Title: | FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy. |
|---|---|
| Authors: | Gracilla DE; Tow Center for Developmental Oncology and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York., Menon S; Tow Center for Developmental Oncology and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York., Breese MR; Division of Pediatric Oncology, University of California, San Francisco, San Francisco, California., Lin YP; Division of Pediatric Oncology, University of California, San Francisco, San Francisco, California., Dela Cruz FS; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York., Feinberg TY; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York., de Stanchina E; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York., Galic AF; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York., Allegakoen H; Division of Pediatric Oncology, University of California, San Francisco, San Francisco, California., Perati SR; Division of Pediatric Oncology, University of California, San Francisco, San Francisco, California., Everin N; Tow Center for Developmental Oncology and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York., Vizconde T; Tow Center for Developmental Oncology and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York., Wen NJ; Tow Center for Developmental Oncology and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York., Heslin A; Division of Pediatric Oncology, University of California, San Francisco, San Francisco, California., Somwar R; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York., Ladanyi M; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York., Horlbeck M; Division of Genetics and Genomics, Boston Children's Hospital, Boston, Massachusetts., Weissman JS; Division of Pediatric Oncology, University of California, San Francisco, San Francisco, California., Sweet-Cordero EA; Division of Pediatric Oncology, University of California, San Francisco, San Francisco, California., Bivona TG; Division of Hematology and Oncology, University of California, San Francisco, San Francisco, California.; Chan Zuckerberg Biohub, San Francisco, California., Tulpule A; Tow Center for Developmental Oncology and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York. |
| Source: | Cancer research [Cancer Res] 2026 Jun 01; Vol. 86 (11), pp. 2660-2677. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 2984705R Publication Model: Print Cited Medium: Internet ISSN: 1538-7445 (Electronic) Linking ISSN: 00085472 NLM ISO Abbreviation: Cancer Res Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
